Photrexa cross-linking kit 6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEF9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,270
Award facts
- Contract value 100% obligated
- $12,269.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,269.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Photrexa Cross-Linking Kit 6ML. The delivery order, issued on January 20, 2026, with an ultimate completion date of February 10, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, and designed to support recurring medical supply needs of military healthcare facilities worldwide through December 31, 2036.
DMS Pharmaceutical Group Inc. serves as a critical regional pharmaceutical supplier within the broader $30.3 billion PPV-G GEN V acquisition strategy, which establishes multiple prime vendor contractors to provide comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare operations globally. The company's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system, with its product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty surgical products spanning multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FMEF9?
SPE2DR26FMEF9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FMEF9 worth?
The government has obligated $12,270 on SPE2DR26FMEF9.
Is contract SPE2DR26FMEF9 an order under another contract?
Yes. SPE2DR26FMEF9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEF9 competed?
The extent of competition for SPE2DR26FMEF9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award